These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35550071)

  • 1. Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis.
    Wei Y; Hay JW; Hay AR; Suen SC
    BMC Urol; 2022 May; 22(1):76. PubMed ID: 35550071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy vs surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis.
    Erman A; Masucci L; Krahn MD; Elterman DS
    BJU Int; 2018 Nov; 122(5):879-888. PubMed ID: 30113127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement.
    Shore N; Tutrone R; Efros M; Bidair M; Wachs B; Kalota S; Freedman S; Bailen J; Levin R; Richardson S; Kaminetsky J; Snyder J; Shepard B; Goldberg K; Hay A; Gange S; Grunberger I
    World J Urol; 2018 May; 36(5):801-809. PubMed ID: 29380128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore.
    Chay J; Tung JYM; Su RJ; Aslim EJ; Wong C; Swan G; Chua WJ; Ho HSS; Finkelstein EA
    J Med Econ; 2023; 26(1):1269-1277. PubMed ID: 37800562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness analysis of pharmacotherapy versus prostatic urethral lift as initial therapy for patients with moderate benign prostatic hyperplasia.
    Tung JY; Aslim EJ; Ho HS; Chen C
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jan; 23(1):63-68. PubMed ID: 36342223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States.
    Yee CW; Harvey MJ; Xin Y; Kirson NY
    Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia.
    Chughtai B; Rojanasarot S; Neeser K; Gultyaev D; Fu S; Bhattacharyya SK; El-Arabi AM; Cutone BJ; McVary KT
    PLoS One; 2022; 17(4):e0266824. PubMed ID: 35427376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study.
    Sahakyan Y; Erman A; Bhojani N; Chughtai B; Zorn KC; Sander B; Elterman DS
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):113-118. PubMed ID: 35689083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
    Chen JV; Klein TM; Nesheim J; Mudd PN
    J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of transurethral resection of the prostate vs thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic obstruction.
    Noble SM; Ahern AM; Worthington J; Hashim H; Taylor H; Young GJ; Brookes S; Abrams P; Johnson L; Khan R; Page T; Swami KS; Lane JA
    BJU Int; 2020 Nov; 126(5):595-603. PubMed ID: 32558178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.
    Bjerklund Johansen TE; Baker TM; Black LK
    BJU Int; 2012 Mar; 109(5):731-8. PubMed ID: 21933326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
    Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
    Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations.
    Earnshaw SR; McDade CL; Black LK; Bell CF; Kattan MW
    Pharmacoeconomics; 2010; 28(6):489-505. PubMed ID: 20196623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.
    Verheggen BG; Lee R; Lieuw On MM; Treur MJ; Botteman MF; Kaplan SA; Trocio JN
    J Med Econ; 2012; 15(3):586-600. PubMed ID: 22332704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Shore N; Tutrone R; Roehrborn CG
    Ther Adv Urol; 2019; 11():1756287218820807. PubMed ID: 30719081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.